Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled (12-17 years) Including a Single Open Label Arm (6-11 years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants